Previous close | 18.20 |
Open | 18.20 |
Bid | 18.44 x 200 |
Ask | 18.49 x 200 |
Day's range | 18.05 - 18.49 |
52-week range | 17.56 - 33.99 |
Volume | |
Avg. volume | 1,870,432 |
Market cap | 3.043B |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.37 |
Earnings date | 06 May 2024 - 10 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 29.54 |
Stephen Davis, the CEO of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), has sold 17,714 shares of the company on March 27, 2024, according to a recent SEC filing.
SAN DIEGO, March 15, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 11, 2024, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 8,904 shares of common stock and 5,461 restricted stock units ("RSUs") to three new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employme
SAN DIEGO, March 13, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time.